XERS Stock: Price, Earnings History and SEC Filings
Xeris Biopharma Holdings, Inc. (XERS) last traded at $10.71, down 0.37% on the latest session and up 12.0% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.00 against an analyst estimate of $0.02, a miss of 100.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
XERS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $0.00 | $0.02 | -100.00% |
| Dec 2025 | Mar 2, 2026 | $0.06 | $0.03 | +100.00% |
| Sep 2025 | Nov 6, 2025 | $0.00 | $0.01 | -100.00% |
XERS beat the analyst EPS estimate in 1 of its last 3 reported quarters. Source: Nasdaq.
How XERS reacts to earnings
Across its last 8 earnings releases, XERS moved 11.8% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | Before open | -9.25% |
| 2026-05-07 | Before open | +4.08% |
| 2026-03-02 | Before open | -1.63% |
| 2026-01-08 | Before open | +12.76% |
| 2025-11-06 | Before open | -21.88% |
| 2025-08-07 | Before open | +20.22% |
| 2025-05-08 | Before open | +15.18% |
| 2025-03-06 | Before open | +9.55% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
XERS financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $292M | $554000 | – | 0.2% | $0.00 |
| 2024 | $203M | -$55M | – | -27.0% | $-0.37 |
| 2023 | $164M | -$62M | – | -38.0% | $-0.45 |
| 2022 | $110M | -$95M | – | -85.9% | $-0.70 |
| 2021 | $50M | -$123M | -$97M | -247.5% | $-1.55 |
| 2020 | $20M | -$91M | -$81M | -452.2% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for XERS
- 8-K · Oct 14, 2026Other events
- 8-K · Sep 9, 2026Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 17, 2026Unregistered share sale, Other events
- 8-K · Jun 30, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 11, 2026Unregistered share sale, Other events, Financial statements and exhibits
- 8-K · Jun 5, 2026Shareholder vote
- 10-Q · May 7, 2026
- 8-K · May 7, 2026Results of operations
Insider filing activity
XERS insiders filed 12 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
XERS news
- Can Corcept Therapeutics Stock Rally 40% After This Dip?Oct 26, 2026 · trefis.com
- Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026Oct 22, 2026 · finance.yahoo.com
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. (XERS) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. Its fiscal year ends in December.